Chronic T-type Ca2+ channel blockade with mibefradil in hyperinsulinemic, insulin-resistant and hypertensive rats
Why the study?
Does mibefradil prevent or reverse hyperinsulinemia, hypertriglyceridemia, and hypertension in fructose-fed rats?
Population
Male Sprague-Dawley rats.
Comparison
Mibefradil 30 mg/kg/day orally for 6 weeks or as… vs Untreated control rats and untreated…
Design
Preclinical
Follow-up
6 weeks
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change clinical practice; hypothesis-generating for T-type calcium channel blockade in insulin resistance.
Structured PICO
Does mibefradil prevent or reverse hyperinsulinemia, hypertriglyceridemia, and hypertension in fructose-fed rats?
P
Population
Male Sprague-Dawley rats (n=24 in prevention study: control n=6, control-treated n=5, fructose n=7, fructose-treated n=6; plus a separate reversal study cohort of 8-week-treated fructose-hypertensive rats and age-matched controls).
I
Intervention
Mibefradil 30 mg/kg/day orally for 6 weeks (prevention protocol) or as a reversal protocol.
C
Comparator
Untreated control rats and untreated fructose-fed rats.
O
Outcome
Plasma insulin levels, plasma triglyceride levels, and systolic blood pressure.surrogate
Mibefradil, a T-type calcium channel blocker, prevents and reverses hyperinsulinemia, hypertriglyceridemia, and hypertension in a rat model of insulin resistance.
Cite This Study
Subodh Verma (1997) studied this question.